GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
HbA1c
glucagon-like peptide-1 receptor agonist
insulin
meta-analysis
systematic review
type 2 diabetes mellitus
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
28
07
2018
revised:
23
09
2018
accepted:
26
09
2018
pubmed:
3
10
2018
medline:
30
5
2019
entrez:
2
10
2018
Statut:
ppublish
Résumé
Current guidelines recommend that antihyperglycaemic treatment in patients with type 2 diabetes not achieving the HbA The review was registered on PROSPERO (CRD42017079547). PubMed, Scopus, CENTRAL, and ClinicalTrials.gov were searched until July 2018. All randomized controlled trials (RCTs) reporting HbA Out of 1885 retrieved papers, 13 RCTs were included in the review. Compared with BP/BB, GLP-1RA/insulin combinations were associated with a similar HbA The present review supports treatment intensification with GLP-1RA added to insulin versus BP/BB in uncontrolled type 2 diabetes. This could provide similar antihyperglycaemic efficacy while leading to weight loss and sparing of hypoglycaemia and insulin dose. As a consequence, a considerable number of patients with type 2 diabetes could be potentially shifted from BP/BB to GLP-1RA/insulin combinations.
Sections du résumé
BACKGROUND
Current guidelines recommend that antihyperglycaemic treatment in patients with type 2 diabetes not achieving the HbA
METHODS
The review was registered on PROSPERO (CRD42017079547). PubMed, Scopus, CENTRAL, and ClinicalTrials.gov were searched until July 2018. All randomized controlled trials (RCTs) reporting HbA
RESULTS
Out of 1885 retrieved papers, 13 RCTs were included in the review. Compared with BP/BB, GLP-1RA/insulin combinations were associated with a similar HbA
CONCLUSIONS
The present review supports treatment intensification with GLP-1RA added to insulin versus BP/BB in uncontrolled type 2 diabetes. This could provide similar antihyperglycaemic efficacy while leading to weight loss and sparing of hypoglycaemia and insulin dose. As a consequence, a considerable number of patients with type 2 diabetes could be potentially shifted from BP/BB to GLP-1RA/insulin combinations.
Substances chimiques
Blood Glucose
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3082Informations de copyright
© 2018 John Wiley & Sons, Ltd.